Abstract: A method of quantifying sodium concentration can include extracting one or more bi-T2 sodium signals from one or more echo time acquisitions. The method can include separating, via a matrix equation including at least one of T2 decays or T2* decays of mono-T2 sodium and bi-T2 sodium, an intensity of the one or more bi-T2 sodium signals from an intensity of one or more mono-T2 sodium signals. The method can include quantifying bi-T2 sodium concentration, mono-T2 sodium concentration, and total sodium concentration based on the one or more echo time acquisitions. The one or more echo time acquisitions can be performed with single-quantum sodium excitations.

Abstract: Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

Abstract: Embodiments of recombinant HIV-1 gp120 proteins that contain a V1 deletion are disclosed. Also provided are gp140, gp145, and gp160 proteins containing the V1 deletion, as well as HIV-1 Env ectodomain trimers containing protomers containing the V1 deletion. Nucleic acid molecules encoding these proteins are also provided. In several embodiments, the disclosed recombinant HIV-1 proteins and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

Abstract: A system includes an eye tracker having a camera, the eye tracker being configured and arranged to track an eye movement of a subject, and a processor in communication with the eye tracker, the processor being configured and arranged to create a dataset of the eye movement, generate a plot of the dataset, the plot reflecting a timecourse of eye position versus time, and identify one or more streaking vertical lines in the plot to indicate a deficit in a cranial nerve function.

Abstract: A processing technique for creating nanowires and hierarchically porous micro/nano structures of ceramic materials is provided. The process includes evaporation of micron-sized water droplets containing dissolved organic salts on heated substrates followed by thermal decomposition of the deposited material. The micron-sized droplets may be generated by supercritical CO2 assisted nebulization, in which high-pressure streams of aqueous solution and supercritical CO2 are mixed, followed by controlled depressurization through a fine capillary. Rapid evaporation takes place on the heated substrates and structures are generated due to CO2 effervescence from the droplets and evaporation of water, along with the pinning of the three phase contact line. Depending on the mass deposited, a mesh of nano-wires or membrane-like structures may result. Sintering of the membrane-like scaffolds above the decomposition temperature of the organic salt creates nanopores within the structures, creating a dual hierarchy of pores.

Abstract: This application relates to methods for overcoming or preventing resistance of a KRAS mutant cancer cell to a growth inhibition and/or cell death induction by a KRAS inhibitor or a SHP2 inhibitor, as well as to methods for enhancing sensitivity of a KRAS mutant cancer cell to a KRAS inhibitor or a SHP2 inhibitor. The application further relates to methods of treating a KRAS mutant cancer in a subject, the method comprising administering to the subject an effective amount of a KRAS inhibitor or a SHP2 inhibitor and an inhibitor of expression or function or a degrader or a binding partner of one or more of various proteins described herein. Related pharmaceutical compositions and kits are also disclosed.

Abstract: The present disclosure provides methods of treating an inflammatory skin disease (e.g., psoriasis) in a subject by administering an inhibitor of Hypoxia Inducible Factor 1? (HIF1?) or an inhibitor of glucose transporter 1 (Glut1). The present disclosure also provides topical formulations comprising an inhibitor of HIF1? or an inhibitor of Glut1.

Abstract: A method of manufacturing a microfluidic analytical device comprising providing a top lamination layer and a bottom lamination layer, wherein each of the top lamination layer and bottom lamination layer comprises an outer layer and an inner layer, cutting out one or more channel spaces from the at least one of the top lamination layer and the bottom lamination layer, wherein the one or more channel spaces form a microfluidic path, positioning at least one middle layer between the top lamination layer and the bottom lamination layer, such that each of the two inner layers face the at least one middle layer, and subjecting the top lamination layer and the bottom lamination layer to a process, wherein the process allows both the inner layers to permeate substantially through the at least one middle layer.

Abstract: The invention relates to methods for simultaneously measuring transcription, chromatin accessibility, surface markers, and immune receptor sequence of a biological sample at the single-cell level, comprising one or more cells.

Abstract: Exemplary apparatus can be provided that can comprise a plurality of antennas; a plurality of conversion systems, each capable of accepting and/or producing one or more digital signals; a circuit (e.g., radio circuit) configured to couple the antennas to the conversion systems; and computer arrangement configurable to selectively control operation of the conversion systems according to one or more predetermined criteria. In some embodiments, the conversion systems can be configured to utilize different sampling rates and/or quantization resolutions and/or to accept and/or produce different numbers of digital signals. Exemplary conversion systems can be enabled/disabled such that one or more can operate simultaneously based on, e.g., subframe timing of received signal, predetermined schedule, power or energy of s, availability of reference signals, channel coherence time, and apparatus energy consumption.

Abstract: The present disclosure is related to systems and methods to be used as aids in the diagnosis of risk for oral cancer, potentially malignant oral lesion (PMOL), and/or oral epithelial dysplasia (OED) by identifying cellular phenotype characteristics of cell samples, including percentage of mature squamous cells, presence or absence of nuclear actin in mature squamous cells, percentage of non-mature squamous cells, percentage of small round cells, percentage of white blood cells, and percentage of lone nuclei.

Abstract: This application relates to isolated antibodies, or antigen-binding fragments thereof, that bind to at least one isoform of cluster of differentiation 97 (CD97), also known as adhesion G protein-coupled receptor E5 (ADGRE5), antibody-drug conjugates comprising such antibodies or antigen-binding fragments, as well as polynucleotides and vectors that encode for such antibodies or antigen-binding fragments. This application further relates to methods of producing the antibodies or antigen-binding fragments and using the antibodies or antigen-binding fragments for treatment of diseases.

Abstract: Provided are compositions and methods for making a diploid yeast having heterozygosity for at least one chromosome. The method includes mating haploid yeast having at least a first modified chromosome comprising a synthetic chromosome suitable for recombination-site-mediated evolution (as a SCRaMbLE-ready modification). The SCRaMbLE-ready modification includes introduced site-specific recombinase recognition sites that can be recognized by a recombinase. Yeast that have at least one SCRaMbLE-ready modification of a chromosome are mated with a haploid yeast devoid of the SCRaMbLE-ready modification to obtain diploid SCRaMbLE-ready yeast. Subsequent to mating the haploid SCRaMbLE-ready yeast to yeast devoid of the SCRaMbLE-ready modification the method includes using the recombinase to recombine the first modified chromosome to obtain heterozygous diploid yeast comprising at least one recombined (SCRaMbLEd) chromosome and a homologous non-SCRaMbLEd chromosome.

Abstract: Exemplary systems, methods and computer-accessible medium according to exemplary embodiments of the present disclosure can be used to implement a zero-copy data-coherent shared-memory IPC data exchange mechanism. The exemplary procedures, systems, computer accessible medium and/or methods can operate standalone or in combination with underlaying IPC tools. When combined with underlying tools, the exemplary systems, methods and computer-accessible medium does not need to implement the same IPC tool standard. The exemplary procedures, system and/or methods can implement an IPC tool in its entirety, or partially, and it can add functionality to existing IPC tools. The exemplary procedures, system and/or methods can implement a shared memory buffer mechanism, where both a sender process and a receiver process use the same shared memory space.

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to glioma-associated oncogene (Gli) expression. More particularly, this disclosure relates to bicyclic compounds and pharmaceutical compositions thereof, methods of inhibiting Gli expression with these compounds, and methods of treating diseases related to Gli expression.

Abstract: This application provides methods of inhibiting an inflammation- or hypoxia-induced death of a cell involving inhibiting an RNF213 signaling pathway. The application further provides methods of preventing or treating various diseases and disorders in a subject involving administering to the subject an inhibitor of expression of RNF213 protein or an inhibitor of one or more functions of the RNF213 protein. The application still further provides methods for enhancing the effectiveness of a cancer treatment in a subject where the cancer involves a hypoxic tumor microenvironment involving co-administering the cancer treatment with an inhibitor or activator of different functions of the RNF213 protein. The application also provides methods of eliminating drug-resistant tumor cells by co-administering an inhibitor of the expression of RNF213 protein or by inhibiting or activating specific functions of the RNF213 protein.

Abstract: A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode, the anode, or both the cathode and the anode with light having a narrow band of wavelengths corresponding to the respective band gaps of the electrode active materials.

Abstract: The present invention relates to compounds of Formula (I): where R1, R2, X, s, and p are as defined herein. The present invention also relates to compounds of Formula (II), Formula (III), and: where R1a, R1b, R1d, R2a, R2b, R3b, X, Z, Z1, Z2, s, and p are as defined herein. Methods of using these compounds to regulate Cav2.2.target double-stranded RNA and to treat diseases and disorders, e.g., chronic pain, are also disclosed.

Abstract: Exemplary system, method and computer-accessible medium, according to exemplary embodiments of the present disclosure, can be used to couple, connect, associate, combine, link, or integrate inter-process communication tools (e.g., underlying inter-process communication (IPC) tools), and provide applications with a coupled IPC API (“application programming interface”), potentially different from that of the underlying IPC tools it relies upon. The exemplary procedures, system and/or methods can differentiate between the IPC API provided to an application by the present disclosure, and the IPC API(s) of the underlying tool(s) that is (are) being coupled to. The exemplary procedures, system and/or methods can integrate IPC tools when, e.g.

Abstract: A system includes one or more processors and one or more memories having instructions stored thereon which, when executed by the one or more processors, cause the one or more processors to perform operations include receiving detected ocular landmarks in a subject, determining ocular parameters based on the detected ocular landmarks, and determining, based on the ocular parameters, a coarse calibration output. The operations include receiving, eyetracking data relating to an eye movement made by the subject, determining a landing position of the eye at the end of the eye movement, sending a signal to display a target at the landing position on a screen, and receiving, from the subject, an input including a response relating the landing position to a gaze parameter of the subject. The gaze parameter is associated with the eye movement. The operations include updating the coarse calibration output based on the input.